City Diagnostics (Nasik) Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.12 M
- Company Age 30 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.30 M
- Revenue Growth -17.90%
- Profit Growth 15.74%
- Ebitda 26.86%
- Net Worth -10.23%
- Total Assets 7.52%
About City Diagnostics (Nasik)
City Diagnostics (Nasik) Private Limited (CDNPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 September 1994 and has a history of 30 years and five months. Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹0.30 M.
Pranjali Joshi and Tushar Joshi serve as directors at the Company.
Company Details
-
Location
Nashik, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85100MH1994PTC080779
-
Company No.
080779
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Sep 1994
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at City Diagnostics (Nasik)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pranjali Joshi
|
Director | 23-Feb-2022 | Current |
|
Tushar Joshi
|
Director | 22-Mar-2021 | Current |
Financial Performance of City Diagnostics (Nasik).
City Diagnostics (Nasik) Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 17.9% decrease. The company also saw a substantial improvement in profitability, with a 15.74% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of City Diagnostics (Nasik)?
In 2021, City Diagnostics (Nasik) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.30 M
₹0
Charges Breakdown by Lending Institutions
- Janlaxmi Co-Operative Bank Ltd : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Dec 1994 | Janlaxmi Co-Operative Bank Ltd | ₹0.30 M | Open |
How Many Employees Work at City Diagnostics (Nasik)?
Unlock and access historical data on people associated with City Diagnostics (Nasik), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of City Diagnostics (Nasik), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped City Diagnostics (Nasik)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
